Diagnosis and treatment of LS. (A) Time from the most recent immunotherapy to the development of LS (a single patient who received a CD19-targeted antibody-drug conjugate is not shown here, but this patient developed LS 1.2 months after therapy). Boxes represent median value and upper and lower quartiles with error bars representing the range of reported values. Patient E-069 received inotuzumab and blinatumomab in the same general timeframe but was categorized as inotuzumab being the more recent. (B) Age at initial diagnosis and age at the time of LS. Red indicates those who were diagnosed with infant ALL; green indicates those who were within the pediatric/YA age group; blue indicates those who were aged >39 years at the time of initial diagnosis. (C) Molecular/cytogenetic abnormalities seen before and after LS. (D) Location of LS at time of presentation. YA, young adult.